δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches. - Wikidata - wikimedia - TriplyDB

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

http://www.wikidata.org/entity/Q37907409

about

SIRT1: A Novel Target for the Treatment of Muscular Dystrophies SERCA2a gene therapy can improve symptomatic heart failure in δ-sarcoglycan-deficient animals.(-)-Epicatechin improves mitochondrial-related protein levels and ameliorates oxidative stress in dystrophic δ-sarcoglycan null mouse striated muscle.Progress in gene therapy of dystrophic heart disease.Myocardial Contractile Dysfunction Is Present without Histopathology in a Mouse Model of Limb-Girdle Muscular Dystrophy-2F and Is Prevented after Claudin-5 Virotherapy.Mutation in δ-Sg Gene in Familial Dilated Cardiomyopathy.Cell-matrix interactions in muscle disease.The effects of resveratrol and SIRT1 activation on dystrophic cardiomyopathy.Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F Dietary Flaxseed Mitigates Impaired Skeletal Muscle Regeneration: in Vivo, in Vitro and in Silico Studies.Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy.Na+-H+ exchanger and proton channel in heart failure associated with Becker and Duchenne muscular dystrophies.

P2860

Q26748736-C9E339F0-BCD1-4B72-B911-F012086DB115 Q34063645-8292DD2D-95F6-42CB-99CE-A140B6D38AE9 Q34674977-E028ECC1-A3BF-4333-A4A8-598AADB66D41 Q36773242-C5F6B4EF-937F-4DAD-ABE3-568A50EC0456 Q37474934-DC0EB7E2-AC89-48DE-AD18-BE3E0169D98B Q37713578-7EE7B61B-DE6B-490D-8C31-1DD2E41A2920 Q37944530-85DA8702-BBC5-4F08-B1DC-E47C85CA7B8A Q38537368-15BC64C2-A422-43EC-898C-D4E40A36DFD9 Q38630255-33C9605B-BD2D-4952-B137-772CB9DFD564 Q38704564-CAAF8EBC-FFBC-46C3-BD4E-73C04AD02208 Q39962189-15F5A276-D0C3-4C4B-BC10-51816700702A Q51732372-63449DC9-F1CA-4492-A9EA-5D04978BEDA4

P2860

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

http://www.wikidata.org/entity/Q37907409

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

@en

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

@nl

type

label

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

@en

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

@nl

prefLabel

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

@en

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

@nl

P1433

Q37907409-F7FFE28D-5F68-4E09-9BED-A0A5D8188E02

P1476

Q37907409-9E0D53C8-66AE-4503-86FB-37989866B647

P2093

Q37907409-9B0C5BD0-DD4E-43EF-A044-C9C5FADAA2FE

Q37907409-E75EB82F-2466-4876-8C79-AB4642DD7C43

P2860

Q37907409-015D0BCB-0E23-496C-AFC0-3904AFB6CDBE

Q37907409-01EB3816-2035-4A17-A6E5-823B228CBDC0

Q37907409-036F9996-BBE5-44A7-BC4E-163DE1C3A141

Q37907409-0378CFE9-AF90-4FBE-AEEB-B3886FE8AFB4

Q37907409-064F09C5-81A5-427A-B991-BCAB002E8EF6

Q37907409-07E7755B-E65F-41DC-9C4C-4A93093CD84A

Q37907409-0A745888-4B0D-4387-AE1A-6F8E2B10415F

Q37907409-0E2DB83D-6111-4E9C-A79E-9002E1C2A5D2

Q37907409-0EC2BE4F-B151-4C57-AC2C-858B4BCD525D

Q37907409-11736916-E974-40FA-A2EC-32765A4B2CB9

P2888

Q37907409-C00E69D8-1E00-4648-8219-DC7BF46FC60F

P304

Q37907409-805C7940-C702-4383-A9B3-F07F0D64BBD0

P31

Q37907409-3C67DD60-C4D9-46DC-8266-9FDFA4995660

P356

Q37907409-6A67A1AB-1F1F-438E-A7D4-265EDAE532CF

P433

Q37907409-D4B7C329-AD7E-4A91-A245-1CCC692D9413

P478

Q37907409-BDA49E70-5617-4E92-8297-867EF9EC931B

P577

Q37907409-F39D2572-4578-45F1-9F17-3C96DA2D7954

P5875

Q37907409-7D71B3DD-68FD-4093-979D-C29BE204CDE0

P6179

Q37907409-07FDC07D-417C-4BC9-B492-E35D449E50BB

P698

Q37907409-DE30595D-7D68-4162-8CFC-72B49D6C4A2A

P932

Q37907409-ADCCA118-82EC-49F2-8B33-7B38BAB3FEC4

P356

P1433

Skeletal Muscle

P1476

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

@en

P2093

Alison M Blain

http://www.w3.org/2001/XMLSchema#string

Volker W Straub

http://www.w3.org/2001/XMLSchema#string

P2860

Sarcoglycan subcomplex expression in normal human smooth muscle

Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene

Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein

Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy

Molecular organization of sarcoglycan complex in mouse myotubes in culture

Mutations in the delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2)

Sarcoglycan isoforms in skeletal muscle

Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy

rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy

Localization of sarcoglycan, neuronal nitric oxide synthase, beta-dystroglycan, and dystrophin molecules in normal skeletal myofiber: triple immunogold labeling electron microscopy

P2888

P304

13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2044-5040-1-13

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51529524

http://www.w3.org/2001/XMLSchema#string

P6179

1018355328

http://www.w3.org/2001/XMLSchema#string

P698

21798091

http://www.w3.org/2001/XMLSchema#string

P932

3156636

http://www.w3.org/2001/XMLSchema#string